Medical Biochemistry: Structure, Classification, and Metabolism of Proteins and Lipids

Course Overview and Learning Objectives

• Academic Scope of Medical Biochemistry II (BSN 124):

  • Integrates the chemical structures, physical properties, catalytic functions, and metabolic pathways of biological macromolecules, focusing primarily on proteins, lipids, enzymes, hormones, nucleic acids, and specialized tissues.
  • Explores the bioenergetics of catabolic and anabolic pathways, molecular mechanisms of metabolic control, inborn errors of metabolism, and clinical laboratory diagnostics.

• Expected Learning Outcomes:

  • Describe the comprehensive chemical structures, systematic classifications, and biological functions of proteins and lipids.
  • Relate lipid metabolic pathways to systemic energy generation, storage, and physiological utilization in the human body.
  • Correlate the intermediary metabolism of amino acids and fatty acids with human physiology and clinical pathophysiology.
  • Detail the catalytic mechanisms, kinetics, inhibition, and clinical diagnostic roles of enzymes, alongside hormonal signaling systems.
  • Explain the specialized biochemical functions and metabolic interrelationships of distinct body tissues, including the brain, liver, erythrocytes, skeletal muscle, and adipose tissue.

Protein Biology and Functional Diversity

• Fundamental Definition and Abundance:
  • Proteins are unbranched polymers composed of L-$\alpha$-amino acids joined together by covalent peptide linkages.
  • They represent the most abundant and functionally diverse class of biomolecules in living systems.
  • The precise sequence and linear order of amino acids in a polypeptide chain dictate the higher-order three-dimensional conformation and biological specificity of the protein.

• Functional Classes and Biological Roles:
  • Structural Proteins: Provide mechanical support, architectural integrity, and tensile strength to cells and tissues.
  • Collagen: Major structural component of connective tissues, including tendons, cartilage, bone matrix, and ligaments.
  • Keratin: Structural fibrous protein present in hair, epidermis, wool, and nails.
  • Contractile Proteins: Facilitate coordinated mechanical movement and tension generation in muscle and non-muscle systems.
  • Myosin and Actin: Function interactively within the sarcomere to mediate muscle fiber contraction and intracellular motility.
  • Transport Proteins: Facilitate the selective translocation of essential inorganic and organic molecules across membranes or through systemic circulation.
  • Hemoglobin: Tetrameric erythrocyte protein responsible for transporting molecular oxygen ($\text{O}_2$) from the lungs to peripheral tissues.
  • Lipoproteins: Macromolecular lipid-protein complexes that transport hydrophobic triglycerides, phospholipids, and cholesterol throughout aqueous plasma.
  • Plasma Albumin: Maintains oncotic pressure and serves as a non-specific carrier for free fatty acids, bilirubin, hormones, and pharmaceutical agents.
  • Storage Proteins: Serve as intracellular or extracellular reservoirs of essential nutrients and metal ions.
  • Casein: Primary nutritional storage protein present in mammalian milk.
  • Ferritin: Iron storage complex located in the spleen, liver, and bone marrow that sequesters toxic ferric ions.
  • Hormone (Signaling) Proteins: Coordinate physiological activities and homeostatic regulation by transmitting biochemical signals throughout the body.
  • Insulin: Pancreatic polypeptide hormone that regulates systemic blood glucose levels by promoting cellular glucose uptake and anabolic storage.
  • Growth Hormone: Pituitary protein regulating somatic growth, cellular proliferation, and metabolic rate.
  • Enzymatic Proteins: Catalyze specialized biochemical reactions in cellular compartments with high efficiency and substrate specificity.
  • Sucrase: Hydrolase that catalyzes the conversion of sucrose into glucose and fructose.
  • Trypsin: Pancreatic serine protease that cleaves peptide bonds adjacent to basic amino acid residues.
  • Protective (Defense) Proteins: Recognize, neutralize, and destroy pathogenic microorganisms and foreign substances.
  • Immunoglobulins (Antibodies): Specialized glycoproteins synthesized by plasma cells that bind antigens and stimulate immune responses.

Chemical Structure and Classification of Amino Acids

• General Molecular Architecture of Amino Acids:
  • There are $20$ standard amino acids commonly found as constituents of mammalian proteins.
  • Each amino acid features a central carbon atom designated as the $\alpha$-carbon ($\text{C}_\alpha$).
  • Bonded to the $\alpha$-carbon are four distinctive chemical moieties:
  • A basic primary amino group ($-\text{NH}_2$).
  • An acidic carboxylic acid group ($-\text{COOH}$).
  • A hydrogen atom ($-\text{H}$).
  • A distinctive side chain, designated the $R$-group, which confers unique chemical and physical properties.
  • Proline represents a notable structural exception, containing a secondary amino group (an imino group) formed by cyclization of its side chain back to the $\alpha$-carbon.
  • At physiological $pH$ ($\approx pH\,7.4$), the carboxyl group exists in its dissociated carboxylate state ($-\text{COO}^-$), while the amino group is protonated ($-\text{NH}_3^+$).

• Nomenclature, Three-Letter Abbreviations, and One-Letter Coding Conventions:
  • Every standard amino acid is assigned an official three-letter abbreviation and a corresponding single-letter symbol governed by specific designation rules:

• Rule 1 — Unique First Letter:
  • Cysteine: Cys = $\text{C}$
  • Histidine: His = $\text{H}$
  • Isoleucine: Ile = $\text{I}$
  • Methionine: Met = $\text{M}$
  • Serine: Ser = $\text{S}$
  • Valine: Val = $\text{V}$

• Rule 2 — Priority for Most Commonly Occurring Amino Acids:
  • Alanine: Ala = $\text{A}$
  • Glycine: Gly = $\text{G}$
  • Leucine: Leu = $\text{L}$
  • Proline: Pro = $\text{P}$
  • Threonine: Thr = $\text{T}$

• Rule 3 — Phonetic Association or Similar Sounding Names:
  • Arginine: Arg = $\text{R}$ ("aRginine")
  • Asparagine: Asn = $\text{N}$ (contains N; amide)
  • Aspartate: Asp = $\text{D}$ ("asparDic acid")
  • Glutamate: Glu = $\text{E}$ ("glutEmate")
  • Glutamine: Gln = $\text{Q}$ ("Q-tamine")
  • Phenylalanine: Phe = $\text{F}$ ("Fenylalanine")
  • Tyrosine: Tyr = $\text{Y}$ ("tYrosine")
  • Tryptophan: Trp = $\text{W}$ (double aromatic ring in molecule, visualizes as a "W")

• Rule 4 — Letter Close to Initial Letter and Ambiguous Codes:

  • Aspartate or Asparagine (unresolved): Asx = $\text{B}$ (letter immediately preceding/near $\text{A}$)

  • Glutamate or Glutamine (unresolved): Glx = $\text{Z}$

  • Lysine: Lys = $\text{K}$ (letter alphabetically close to $\text{L}$)

  • Undetermined Amino Acid: Undetermined = $\text{X}$

  • Classification Based on Side Chain Polarity and Charge:

• Non-polar (Hydrophobic) Amino Acids:

  • Contain hydrocarbon side chains that neither gain nor lose protons at physiological $pH$, nor participate in hydrogen bonding or ionic bridges.
  • Tend to cluster within the interior hydrophobic core of globular proteins in aqueous solutions.
  • Glycine: Smallest amino acid; side chain is a hydrogen atom ($-\text{H}$; $pK_1 = 2.3$, $pK_2 = 9.6$).
  • Alanine: Methyl side chain ($-\text{CH}_3$).
  • Valine: Branched isopropyl group ($-\text{CH(CH}_3)_2$).
  • Leucine: Isobutyl side chain ($-\text{CH}_2\text{-CH(CH}_3)_2$).
  • Isoleucine: sec-Butyl group with two chiral centers ($-\text{CH(CH}_3)\text{-CH}_2\text{-CH}_3$).
  • Phenylalanine: Benzyl side chain ($-\text{CH}_2\text{-C}_6\text{H}_5$).
  • Tryptophan: Bulky bicyclic indole ring system linked via a methylene bridge ($-\text{CH}_2\text{-indole}$).
  • Methionine: Thioether non-polar side chain ($-\text{CH}_2\text{-CH}_2\text{-S-CH}_3$).
  • Proline: Cyclic pyrrolidine ring incorporating the $\alpha$-amino nitrogen, producing rigid steric constraints.

• Uncharged Polar Amino Acids:
  • Possess side chains that have a net charge of zero at neutral $pH$ ($pH\,7.0$), but contain electronegative atoms capable of participating in hydrogen bonding with water or other polar residues.
  • Serine: Hydroxymethyl group ($-\text{CH}_2\text{OH}$).
  • Threonine: Secondary alcohol side chain ($-\text{CH(OH)-CH}_3$).
  • Tyrosine: Phenolic hydroxyl group ($-\text{CH}_2\text{-C}_6\text{H}_4\text{-OH}$; $pK_1 = 2.2$, $pK_2 = 9.1$, $pK_3 = 10.1$).
  • Asparagine: Carboxamide side chain ($-\text{CH}_2\text{-CONH}_2$).
  • Glutamine: Extended carboxamide chain ($-\text{CH}_2\text{-CH}_2\text{-CONH}_2$).
  • Cysteine: Reactive sulfhydryl (thiol) side chain ($-\text{CH}_2\text{-SH}$; $pK_1 = 1.7$, $pK_2 = 8.3$, $pK_3 = 10.8$), which can undergo oxidation to form covalent disulfide bonds.

• Acidic Amino Acids (Negatively Charged at Physiological pH):
  • Function as proton donors; their side chains contain carboxylic acid moieties that dissociate at neutral $pH$, giving them a net negative charge.
  • Aspartic Acid (Aspartate): Side chain carboxylate ($-\text{CH}_2\text{-COOH}$; $pK_1 = 2.1$, $pK_2 = 3.9$, $pK_3 = 9.8$).
  • Glutamic Acid (Glutamate): Extended side chain carboxylate ($-\text{CH}_2\text{-CH}_2\text{-COOH}$; $pK_1 = 2.1$, $pK_2 = 4.3$, $pK_3 = 9.7$).

• Basic Amino Acids (Positively Charged at Physiological pH):
  • Act as proton acceptors; their nitrogenous side chains carry a positive charge at physiological $pH$.
  • Histidine: Imidazole ring ($-\text{CH}_2\text{-imidazole}$; $pK_1 = 1.8$, $pK_2 = 6.0$, $pK_3 = 9.2$); because its side-chain $pK_a$ is near neutral, it can serve as a physiological acid-base buffer in enzyme catalytic centers.
  • Lysine: Terminal primary amino group on an aliphatic chain ($-\text{(CH}_2)_4\text{-NH}_3^+$; $pK_1 = 2.2$, $pK_2 = 9.2$, $pK_3 = 10.5$).
  • Arginine: Guanidinium group ($-\text{(CH}_2)_3\text{-NH-C(NH}_2)=\text{NH}_2^+$; $pK_1 = 2.2$, $pK_2 = 9.0$, $pK_3 = 12.5$), which remains fully protonated at physiological $pH$.

Optical, Amphoteric, and Physical Properties of Amino Acids

• Optical Activity and Chirality:
  • The $\alpha$-carbon of all amino acids (with the single exception of glycine) is asymmetric, bonded to four distinct chemical functional groups, creating a chiral center.
  • Chiral amino acids exist as non-superimposable mirror images known as enantiomers, designated as either $\text{D}$ or $\text{L}$ configurations.
  • All naturally occurring amino acids incorporated into mammalian proteins during ribosomal translation belong exclusively to the $\text{L}$-stereochemical configuration.
  • Glycine Exception: Glycine has two hydrogen atoms attached to its $\alpha$-carbon; it lacks a chiral center and is optically inactive.

• Amphoteric Nature and Zwitterion Formation:
  • Both the $\alpha$-amino ($-\text{NH}_2$) and $\alpha$-carboxyl ($-\text{COOH}$) groups are ionizable moieties capable of donating or accepting protons depending on environmental $pH$.
  • Because amino acids display both acidic and basic properties, they are amphoteric substances (ampholytes).
  • Isoelectric Point ($pI$):
  • The specific $pH$ at which an amino acid carries an equal number of positive and negative charges, resulting in a net electrical charge of zero.
  • At this $pH$, the molecule exists as a dipolar ion, termed a Zwitterion.
  • Alanine Acid-Base Equilibrium: Alanine displays two ionization constants: $pK_a^1 = 2.34$ (dissociation of the carboxyl group) and $pK_a^2 = 9.69$ (deprotonation of the amino group).
  • Its isoelectric point is calculated as:       $pI = \frac{pK_a^1 + pK_a^2}{2} = \frac{2.34 + 9.69}{2} = 6.01$
  • At $pH < 2.0$, alanine is fully protonated and exists as a net positive monocation ($+\text{H}_3\text{N-CH(CH}_3)\text{-COOH}$; charge = $+1$).
  • At $pH \approx 6.01$, alanine is a zwitterion ($+\text{H}_3\text{N-CH(CH}_3)\text{-COO}^-$; net charge = $0$).
  • At $pH > 10.0$, alanine is deprotonated into an anionic conjugate base ($\text{H}_2\text{N-CH(CH}_3)\text{-COO}^-$; charge = $-1$).

• Physical Properties of Amino Acids:
  • Amino acids are colorless, crystalline substances with high melting points due to ionic crystal lattice forces.
  • They exhibit high solubility in water and polar solvents, but are insoluble in non-polar organic solvents such as benzene or chloroform.
  • Tyrosine has low solubility in cold water, but dissolves readily in hot water.

Peptide Bond Formation and Higher-Order Protein Structure

• Peptide Bond Chemistry:
  • The covalent link between successive amino acid residues is an amide linkage designated as a peptide bond.
  • Formed through a condensation (dehydration) reaction between the $\alpha$-carboxyl group of one amino acid and the $\alpha$-amino group of another, eliminating one molecule of water ($\text{H}_2\text{O}$).
  • Polypeptide chains possess an intrinsic structural directionality (polarity), extending from the free amino-terminal end ($\text{N}$-terminus) to the free carboxyl-terminal end ($\text{C}$-terminus).

• Hierarchical Levels of Protein Structural Organization:
  • Primary Structure ($1^\circ$):
  • The linear sequence of amino acids linked together by peptide bonds (e.g., $\text{Ala-Leu-Cys-Met}$).
  • Dictated by the genetic code within nuclear DNA; determines all higher structural conformations.
  • Secondary Structure ($2^\circ$):
  • Localized, periodic spatial conformations of the polypeptide backbone stabilized by hydrogen bonds between the carbonyl oxygen ($-\text{C=O}$) and amide hydrogen ($-\text{N-H}$) atoms of peptide linkages.
  • Alpha-Helix ($\alpha$-helix): Right-handed helical coil where each turn spans $3.6$ amino acid residues; stabilized by intrachain hydrogen bonds parallel to the central axis.
  • Beta-Pleated Sheet ($\beta$-pleated sheet): Extended polypeptide strands aligned side-by-side in parallel or antiparallel orientations, stabilized by interstrand hydrogen bonding.
  • Triple Helix: Tightly wound rope-like structural motif characteristic of collagen tropocollagen units.
  • Tertiary Structure ($3^\circ$):
  • The overall three-dimensional folding of a single polypeptide chain into a compact, globular or fibrous architectural conformation.
  • Governed and stabilized by chemical interactions between amino acid side-chain $R$-groups:
    • Hydrophobic Interactions: Association of non-polar side chains buried away from water in the protein core.
    • Hydrophilic Interactions: Surface-oriented interactions between polar residues and external water.
    • Salt Bridges: Electrostatic attractions between oppositely charged basic ($-\text{NH}_3^+$) and acidic ($-\text{COO}^-$) groups.
    • Hydrogen Bonds: Formed between polar functional groups on side chains (e.g., between serine $\text{-OH}$ and peptide backbones).
    • Disulfide Bonds: Covalent linkages ($-\text{S-S-}$) formed by the enzymatic oxidation of two cysteine sulfhydryl groups, providing covalent structural stabilization.

• Quaternary Structure ($4^\circ$):
  • The spatial assembly of two or more independent polypeptide subunits into an oligomeric functional protein complex.
  • Subunits are held together by the same non-covalent interactions that maintain tertiary structure (hydrophobic forces, hydrogen bonds, salt bridges).
  • Hemoglobin Example: Tetrameric complex consisting of two identical $\alpha$-globin chains and two identical $\beta$-globin chains ($\alpha_2\beta_2$).

• Molecular Pathology Case Study — Sickle Cell Anemia:
  • Etiology: Sickle cell anemia is caused by a single point mutation in the gene encoding the $\beta$-globin chain of hemoglobin.
  • Primary Structure Alteration: The codon mutation results in the substitution of a charged, hydrophilic glutamic acid residue by a non-polar, hydrophobic valine residue at position $6$ of the $\beta$-chain ($\text{Glu6Val}$).
  • Higher-Order Structural Cascade: Upon deoxygenation, the hydrophobic valine interacts with a complementary hydrophobic pocket on an adjacent deoxygenated hemoglobin molecule ($\text{HbS}$). This promotes polymer formation and precipitation of hemoglobin into long, insoluble fibrous strands.
  • Pathophysiological Consequences: The intracellular crystalline fibers distort the flexible biconcave erythrocyte into a rigid, sickle-shaped conformation.
  • Sickled red blood cells cannot readily deform to traverse microvascular capillaries, causing microvascular occlusion, tissue hypoxia, painful vaso-occlusive crises, and chronic hemolytic anemia.

Protein Digestion, Absorption, and Turnover

• Sources of the Free Amino Acid Pool:

  • Dietary protein breakdown through gastrointestinal digestion.
  • De novo biosynthesis of non-essential amino acids in the liver.
  • Intracellular protein turnover and degradation of endogenous tissue proteins.

• Protein Turnover:

  • Continuous breakdown and resynthesis of cellular proteins.
  • Serves essential biological functions: removal of misfolded or damaged proteins, degradation of aging cellular structures, and ongoing recycling of metabolic enzymes and peptide hormones.

• Enzymatic Cascade of Dietary Protein Digestion:

  • Oral Cavity: Mastication mechanically fragments food; saliva contains no proteolytic enzymes, resulting in no chemical digestion of proteins in the mouth.
  • Gastric Digestion:
  • Hydrochloric acid ($\text{HCl}$), secreted by parietal cells, reduces gastric $pH$ ($pH\,1\text{--}2$), denaturing globular proteins and opening their structures for enzymatic cleavage.
  • Pepsinogen, secreted by chief cells, undergoes autocatalytic activation into the endopeptidase pepsin, which hydrolyzes internal peptide bonds to generate large oligopeptides.
  • Small Intestinal Digestion:
  • Acidic chyme entering the duodenum stimulates pancreatic secretion of bicarbonate and inactive zymogens.
  • Pancreatic proteases (trypsin, chymotrypsin, and carboxypeptidases) hydrolyze large polypeptides into small peptides (dipeptides and tripeptides) and free amino acids.
  • Intestinal brush-border enzymes (such as aminopeptidases) complete luminal peptide bond cleavage.

• Intestinal Epithelial Absorption:
  • Free amino acids cross the apical brush-border membrane of enterocytes via secondary active transport systems coupled to the inward sodium ($\text{Na}^+$) gradient.
  • This electrochemical driving force is sustained by the basolateral $\text{Na}^+/\text{K}^+\text{-ATPase}$ pump, which hydrolyzes ATP to export three $\text{Na}^+$ ions in exchange for two incoming $\text{K}^+$ ions.
  • Intracellular amino acids exit the basolateral membrane via facilitative transporters and enter the mesenteric venules of the portal venous system for delivery to the liver.

Amino Acid Catabolism: Transamination, Deamination, and Transdeamination

• Two-Stage Catabolic Breakdown:

  • Stage 1: Removal of the $\alpha$-amino group through enzymatic transamination followed by oxidative deamination.
  • Stage 2: Processing and metabolic routing of the remaining carbon skeletons into central energy pathways.

• Transamination Reactions:

  • Transfer of an $\alpha$-amino group from an amino acid to an $\alpha$-keto acid acceptor (predominantly $\alpha$-ketoglutarate, also known as oxoglutarate).
  • Catalyzed by transaminases (aminotransferases), which require pyridoxal phosphate ($\text{PLP}$, derived from vitamin $\text{B}_6$) as an essential coenzyme.
  • Reaction Outcome: Converts the original amino acid into its corresponding $\alpha$-keto acid, while $\alpha$-ketoglutarate is aminated to produce glutamate.
  • Diagnostic Aminotransferases: Alanine aminotransferase ($\text{ALT}$) and Aspartate aminotransferase ($\text{AST}$) are abundant in hepatocytes. When liver parenchymal damage or necrosis occurs, these enzymes leak into systemic circulation in large quantities, functioning as sensitive biomarkers for hepatic injury.

• Oxidative Deamination:

  • The glutamate formed during transamination undergoes deamination within the mitochondrial matrix to release inorganic ammonia ($\text{NH}_3$).
  • Catalyzed by glutamate dehydrogenase ($\text{GDH}$), which uniquely utilizes either $\text{NAD}^+$ or $\text{NADP}^+$ as an electron acceptor.
  • Generates free ammonia ($\text{NH}_3$), $\text{NAD(P)H} + \text{H}^+$, and regenerates $\alpha$-ketoglutarate for additional transamination cycles.

• The Coupled Transdeamination Mechanism:

  • Transdeamination is a coordinated, two-step pathway that channels the amino groups from most amino acids into ammonia in the liver and kidneys.
  • Step 1: Transamination transfers the amino group of an amino acid to $\alpha$-ketoglutarate, generating glutamate.
  • Step 2: Glutamate dehydrogenase oxidatively removes the amino group from glutamate, releasing it as free ammonia ($\text{NH}_3$).
  • Glutamate functions as the central collector and carrier of amino-group nitrogen within intermediary metabolism.

The Urea Cycle and Associated Inborn Errors

• Physiological Purpose and Nitrogen Detoxification:
  • Free ammonium ions ($\text{NH}_4^+$) are neurotoxic at micromolar concentrations.
  • The urea cycle (Krebs-Henseleit cycle) operates primarily in hepatocytes to convert neurotoxic ammonia into non-toxic, water-soluble urea, which is excreted in the urine.

• Inputs and Outputs of the Cycle:
  • Inputs: Free ammonia ($\text{NH}_3$), carbon dioxide ($\text{CO}_2$ / bicarbonate $\text{HCO}_3^-$), the amino acid aspartate (which donates the second nitrogen atom), and $3\text{ ATP}$ molecules (consuming $4$ high-energy phosphate bonds).
  • Outputs: One molecule of urea, fumarate, $2\text{ ADP} + 2\text{ P}_i$, and $1\text{ AMP} + 1\text{ PP}_i$.

• Enzymatic Reactions of the Urea Cycle:

  • Step 1 (Mitochondrial Matrix) — Formation of Carbamoyl Phosphate:
  • $2\text{ ATP} + \text{HCO}_3^- + \text{NH}_3 \rightarrow \text{Carbamoyl phosphate} + 2\text{ ADP} + \text{P}_i$
  • Catalyzed by Carbamoyl Phosphate Synthetase I ($\text{CPS1}$). This is the committed, rate-limiting step.
  • Obligately dependent on the allosteric activator N-acetylglutamate ($\text{NAG}$), synthesized by N-acetylglutamate synthase ($\text{NAGS}$).
  • Step 2 (Mitochondrial Matrix) — Synthesis of Citrulline:
  • Carbamoyl phosphate condenses with ornithine to yield citrulline and release inorganic phosphate ($\text{P}_i$).
  • Catalyzed by Ornithine Transcarbamylase ($\text{OTC}$).
  • Citrulline is transported out of the mitochondria into the cytosol via the ornithine/citrulline antiporter.
  • Step 3 (Cytoplasm) — Synthesis of Argininosuccinate:
  • Citrulline condenses with aspartate in an ATP-dependent reaction.
  • Catalyzed by Argininosuccinate Synthetase I ($\text{ASS1}$).
  • Consumes $1\text{ ATP}$, which is hydrolyzed to $\text{AMP} + \text{PP}_i$, driving the incorporation of aspartate's amino group.
  • Step 4 (Cytoplasm) — Cleavage of Argininosuccinate:
  • Argininosuccinate is cleaved into arginine and fumarate.
  • Catalyzed by Argininosuccinate Lyase ($\text{ASL}$).
  • The released fumarate provides an anaplerotic link to the citric acid cycle.
  • Step 5 (Cytoplasm) — Cleavage of Arginine to Generate Urea:
  • Hydrolytic cleavage of arginine releases urea and regenerates ornithine.
  • Catalyzed by Arginase ($\text{ARG1}$).
  • Ornithine is transported back into the mitochondrial matrix by the ornithine transporter ($\text{ORNT1}$) to initiate another cycle.

• Metabolic Fate of Urea and Clinical Considerations:

  • Synthesized urea diffuses out of hepatocytes into the systemic circulation and is filtered by the renal glomeruli for urinary excretion.
  • A minor fraction of blood urea diffuses into the intestinal lumen, where bacterial urease cleaves it into $\text{CO}_2$ and $\text{NH}_3$.
  • In chronic renal failure, impaired excretion leads to elevated blood urea nitrogen ($\text{BUN}$), increasing urea flux into the gastrointestinal tract and elevating toxic ammonia reabsorption. Treatment includes the oral administration of neomycin to eradicate urease-producing gut bacteria.

• Inborn Errors of the Urea Cycle:
  • Hyperammonemia Type I: Deficiency of Carbamoyl Phosphate Synthetase I ($\text{CPS1}$). Autosomal recessive; marked elevation of blood $\text{NH}_3$, neurological impairment, intellectual disability; estimated incidence of $1\text{ in }100{,}000$.
  • Hyperammonemia Type II: Deficiency of Ornithine Transcarbamylase ($\text{OTC}$). X-linked inheritance; results in elevated blood ammonia, increased glutamine in blood, CSF, and urine, and orotic aciduria due to shunting of accumulated carbamoyl phosphate into cytoplasmic pyrimidine synthesis.
  • Hyperornithinemia (HHH Syndrome): Defect in the mitochondrial ornithine transporter protein ($\text{ORNT1}$ gene). Autosomal recessive; failure to import cytosolic ornithine into mitochondria causes hyperornithinemia, hyperammonemia, and homocitrullinuria, alongside decreased blood urea.
  • Citrullinemia: Deficiency of Argininosuccinate Synthetase ($\text{ASS1}$). Autosomal recessive; elevated blood ammonia and citrulline, with severe citrullinuria ($1\text{--}2\,g/\text{day}$).
  • Argininosuccinic Aciduria: Deficiency of Argininosuccinate Lyase ($\text{ASL}$). Characterized by high levels of arginosuccinate in blood and urine, along with trichorrhexis nodosa (friable, brittle, tufted hair); incidence is approximately $3\text{ in }200{,}000$.
  • Hyperargininemia: Deficiency of Arginase ($\text{ARG1}$). Marked elevation of arginine in blood and CSF. Arginine reabsorption mechanisms are overloaded, leading to excessive urinary excretion of arginine, cysteine, and lysine; incidence is $1\text{ in }100{,}000$.

Carbon Skeleton Degradation and Inborn Errors of Metabolism

• Glucogenic Versus Ketogenic Amino Acids:
  • Following deamination, amino acid carbon skeletons are converted into metabolic intermediates entering amphibolic pathways.
  • Glucogenic Amino Acids: Catabolized into pyruvate, $\alpha$-ketoglutarate, succinyl-CoA, fumarate, or oxaloacetate, which can enter gluconeogenesis to produce glucose.
  • Ketogenic Amino Acids: Catabolized directly into acetyl-CoA or acetoacetyl-CoA, which yield fatty acids or ketone bodies.
  • Purely Ketogenic: Leucine and Lysine.
  • Both Glucogenic and Ketogenic: Isoleucine, Phenylalanine, Tryptophan, and Tyrosine.

• Specific Catabolic Degradation Pathways:
  • Threonine, Glycine, Serine, Alanine, and Cysteine Degradation to Pyruvate:
  • Threonine is oxidized by threonine dehydrogenase ($\text{TDH}$) with $\text{NAD}^+$ to form $2\text{-amino-3-ketobutyrate}$, which is cleaved with $\text{CoA}$ to yield glycine and acetyl-CoA.
  • Glycine can be converted via a $\text{PLP}$-dependent reaction into serine, or cleaved into $\text{CO}_2 + \text{NH}_4^+ + \text{NADH}$.
  • Serine undergoes dehydration and deamination catalyzed by serine dehydratase ($\text{PLP}$-dependent) to yield pyruvate and $\text{NH}_4^+$.
  • Alanine transfers its amino group via alanine aminotransferase ($\text{ALT}$) with $\text{PLP}$ to $\alpha$-ketoglutarate, producing pyruvate and glutamate.
  • Cysteine is degraded in two enzymatic steps to pyruvate.
  • Tryptophan degradation yields alanine in four steps, which is then transaminated to pyruvate.

• Phenylalanine and Tyrosine Catabolic Cascade:
  • Phenylalanine is converted into tyrosine by phenylalanine hydroxylase ($\text{PAH}$), consuming molecular oxygen ($\text{O}_2$) and tetrahydrobiopterin ($\text{BH}_4$):     $\text{Phenylalanine} + \text{BH}_4 + \text{O}_2 \rightarrow \text{Tyrosine} + \text{BH}_2 + \text{H}_2\text{O}$
  • Tyrosine undergoes transamination with $\alpha$-ketoglutarate via tyrosine aminotransferase to form $p\text{-hydroxyphenylpyruvate}$.
  • Oxidation by $p\text{-hydroxyphenylpyruvate dioxygenase}$ forms homogentisate, releasing $\text{CO}_2$.
  • Homogentisate is cleaved by homogentisate 1,2-dioxygenase to produce maleylacetoacetate.
  • Isomerization yields fumarylacetoacetate, which fumarylacetoacetase cleaves into fumarate (glucogenic) and acetoacetate (ketogenic).

• Clinical Disorders of Amino Acid Catabolism:
  • Phenylketonuria (PKU):
  • Deficiency: Hepatic phenylalanine hydroxylase ($\text{PAH}$) deficiency, or defective dihydrobiopterin reductase.
  • Pathophysiology: Phenylalanine accumulates and is diverted into alternative transamination, generating high levels of phenylpyruvate, phenyllactate, and phenylacetate.
  • Clinical Manifestations: Severe intellectual disability, microcephaly, recurrent seizures, hypopigmentation, and a musty/mousy body odor.
  • Management: Lifelong dietary restriction of phenylalanine and supplementation with tyrosine. Individuals with PKU must strictly avoid the artificial sweetener aspartame (aspartyl-phenylalanine-1-methyl ester), which is hydrolyzed in the gut into free phenylalanine.
  • Alkaptonuria:
  • Deficiency: Defect in homogentisate oxidase (homogentisate 1,2-dioxygenase).
  • Clinical Manifestations: Homogentisic acid accumulates and is excreted in urine, which oxidizes to a dark/black color upon standing. Deposition of pigment in cartilage and connective tissues causes ochronosis, leading to severe degenerative arthritis in adulthood.
  • Management: Low-protein diet and high-dose ascorbic acid (vitamin C) to slow oxidation.
  • Maple Syrup Urine Disease (MSUD):
  • Deficiency: Defect in the branched-chain $\alpha$-ketoacid dehydrogenase complex ($\text{BCKDC}$).
  • Amino Acids Involved: Leucine, Isoleucine, and Valine.
  • Pathophysiology: Inability to decarboxylate branched-chain ketoacids (e.g., $\text{leucine} \rightarrow \alpha\text{-ketoisocaproate} \not\rightarrow \text{isovaleryl-CoA}$).
  • Clinical Features: Sweet, maple syrup odor in the urine, poor neonatal feeding, vomiting, ketoacidosis, lethargy, coma, and neurological deterioration.
  • Management: Dietary restriction of branched-chain amino acids.
  • Homocystinuria:
  • Deficiency: Defect in cystathionine $\beta$-synthase ($\text{CBS}$), which converts homocysteine and serine into cystathionine:       $\text{Homocysteine} + \text{Serine} \rightarrow \text{Cystathionine}$
  • Metabolite Accumulation: Homocysteine and methionine accumulate in blood and urine.
  • Clinical Manifestations: Ectopia lentis (downward and inward dislocation of the lens), skeletal deformities, osteoporosis, intellectual disability, and a high risk of thromboembolism.
  • Management: Methionine-restricted, cysteine-supplemented diet, high-dose pyridoxine (vitamin $\text{B}_6$), and antiplatelet therapy.

Lipid Chemistry and Systematic Classification

• General Chemical Properties of Lipids:
  • Lipids comprise a heterogeneous group of water-insoluble, hydrophobic organic molecules.
  • Insoluble in aqueous solutions, but readily soluble in non-polar organic solvents, including ether, chloroform, benzene, and acetone.

• Bloor's Systematic Classification:
  • Simple Lipids: Esters of fatty acids with various alcohols.
  • Fats and Oils: Esters of fatty acids with the trihydric alcohol glycerol, forming triacylglycerols (triglycerides).
  • Waxes: Esters of fatty acids with high-molecular-weight monohydric alcohols.
  • Compound (Complex) Lipids: Esters containing fatty acids, alcohols, and additional chemical functional groups.
  • Phospholipids: Contain an alcohol, fatty acids, and a phosphate group, often linked to a nitrogenous base. Divided into:
    • Glycerophospholipids: Contain a glycerol backbone (e.g., phosphatidylcholine, phosphatidylethanolamine).
    • Sphingophospholipids: Contain an amino alcohol sphingosine backbone (e.g., sphingomyelin).
  • Glycolipids (Glycosphingolipids): Contain carbohydrate moieties attached to a sphingosine-fatty acid (ceramide) complex.
    • Cerebrosides: Simple glycolipids with a single monosaccharide unit (glucose or galactose) linked to ceramide.
    • Gangliosides: Complex glycolipids featuring branched oligosaccharide chains terminated with one or more sialic acid (N-acetylneuraminic acid) residues.
  • Proteolipids: Protein-lipid complexes associated with membrane architectures.

• Derived Lipids: Derivatives produced via the enzymatic or chemical hydrolysis of simple and compound lipids, including:
  • Free fatty acids, glycerol, higher alcohols, and isoprenoids.
  • Steroids and Sterols: Lipid compounds containing a core cyclopentanoperhydrophenanthrene ring system (rings $\text{A}$, $\text{B}$, $\text{C}$, and $\text{D}$), exemplified by cholesterol.

• Structure and Classification of Fatty Acids:
  • Consist of an amphipathic structure: a polar, hydrophilic terminal carboxylic acid group ($-\text{COOH}$) and an extended, non-polar, hydrophobic hydrocarbon chain.
  • Classification by Carbon Chain Length:
  • Short-Chain Fatty Acids (SCFAs): $\le 5$ carbons (e.g., butyric acid, produced via anaerobic bacterial fermentation of dietary fiber in the colon).
  • Medium-Chain Fatty Acids (MCFAs): $6\text{ to }12$ carbons (e.g., caprylic acid, capric acid; found in coconut oil and dairy fat).
  • Long-Chain Fatty Acids (LCFAs): $13\text{ to }21$ carbons (e.g., palmitic acid, oleic acid; primary dietary fats).
  • Very Long-Chain Fatty Acids (VLCFAs): $\ge 22$ carbons (e.g., cerotic acid [$C26:0$], montanic acid [$C28:0$]).
  • Classification by Degree of Saturation:
  • Saturated Fatty Acids: Lack carbon-carbon double bonds ($\text{C=C}$) along the hydrocarbon chain. Pack tightly into solid structures with high melting points.
    • Palmitic acid ($C16:0$).
    • Stearic acid ($C18:0$).
    • Myristic acid ($C14:0$).
  • Monounsaturated Fatty Acids (MUFAs): Contain a single double bond in their hydrocarbon chain.
    • Oleic acid ($C18:1, \Delta^9$ or $18:1\,(\Delta 9Z)$; abundant in olive oil and avocados).
    • Palmitoleic acid ($C16:1$).
  • Polyunsaturated Fatty Acids (PUFAs): Contain two or more double bonds.
    • Linoleic acid ($C18:2, \Delta^{9,12}$; an essential $\text{n-6}$ fatty acid).
    • $\alpha$-Linolenic acid ($C18:3, \Delta^{9,12,15}$; an essential $\text{n-3}$ fatty acid).
    • Arachidonic acid ($C20:4, \Delta^{5,8,11,14}$; $\text{n-6}$ precursor for eicosanoids).
    • Eicosapentaenoic acid (EPA, $C20:5$; $\text{n-3}$ fish oil derivative).
    • Docosahexaenoic acid (DHA, $C22:6$; $\text{n-3}$ fatty acid essential for cerebral and retinal function).

Digestion, Emulsification, and Absorption of Lipids

• Dietary Intake and Gastric Digestion:

  • Average adult daily intake of dietary lipids is approximately $81\,g$.
  • Triacylglycerols (TAGs) constitute over $90\%$ of this dietary intake.
  • Digestion begins in the stomach, catalyzed by an acid-stable lipase (lingual and gastric lipase).
  • Acid-stable lipases preferentially hydrolyze ester bonds in TAGs containing short- and medium-chain fatty acids ($< 12$ carbons), such as those in milk fat.

• Duodenal Emulsification:

  • Hydrophobic lipids enter the duodenum as coarse oil droplets requiring emulsification to increase the accessible surface area for hydrophilic digestive enzymes.
  • Accomplished by two complementary mechanisms:
  • The amphipathic detergent properties of bile salts secreted by the liver and gallbladder.
  • Mechanical mixing driven by gastrointestinal peristalsis.

• Pancreatic Enzymatic Degradation:
  • Triacylglycerol Cleavage: Pancreatic lipase, in the presence of colipase, hydrolyzes fatty acids from the outer $sn\text{-}1$ and $sn\text{-}3$ positions of the glycerol backbone, yielding $2\text{-monoacylglycerol}$ ($2\text{-MAG}$) and two free fatty acids.
  • Cholesteryl Ester Cleavage: Pancreatic cholesteryl ester hydrolase (cholesterol esterase) hydrolyzes cholesteryl esters into free, non-esterified cholesterol and free fatty acids.
  • Phospholipid Cleavage: Phospholipase $\text{A}_2$ hydrolyzes the fatty acid at the $sn\text{-}2$ position of phospholipids, releasing a free fatty acid and a lysophospholipid.

Adipose Lipid Mobilization and Mitochondrial Transport

• Adipose Tissue Lipolysis (Fatty Acid Mobilization):
  • Mobilization breaks down stored intracellular triacylglycerols into free fatty acids and glycerol for transport to energy-demanding peripheral tissues.
  • Triggered by catabolic hormonal signals (epinephrine, norepinephrine, glucagon, cortisol) released in response to hypoglycemia or increased energy demand.

• Intracellular Signaling Cascade in Adipocytes:
  • Step 1: Lipolytic hormones bind to G-protein coupled receptors ($\text{GPCRs}$) on the adipocyte plasma membrane, stimulating adenylyl cyclase.
  • Step 2: Adenylyl cyclase synthesizes cyclic adenosine monophosphate ($\text{cAMP}$) from ATP.
  • Step 3: Elevated $\text{cAMP}$ activates Protein Kinase A ($\text{PKA}$).
  • Step 4: Active $\text{PKA}$ phosphorylates two key downstream targets:
  • Perilipin: The protective coating surrounding the intracellular lipid droplet; phosphorylation rearranges perilipin to expose stored triacylglycerols.
  • Hormone-Sensitive Lipase (HSL): Phosphorylation activates $\text{HSL}$, causing it to translocate to the lipid droplet to hydrolyze triacylglycerols into diacylglycerol and monoacylglycerol intermediates, ultimately producing glycerol and free fatty acids.
  • Step 5 (Circulatory Transport): Released free fatty acids ($\text{FFAs}$) exit adipocytes and bind reversibly to plasma albumin for transport to peripheral tissues (skeletal muscle, myocardium, liver). Glycerol dissolves freely in plasma and travels to the liver, where glycerol kinase phosphorylates it for gluconeogenesis or glycolysis.

• The Carnitine Shuttle:
  • Long-chain fatty acids ($12\text{--}20$ carbons) cannot directly cross the inner mitochondrial membrane to reach the enzymes of $\beta$-oxidation.
  • Cytosolic Activation: Fatty acids are activated on the outer mitochondrial membrane by fatty acyl-CoA synthetase (thiokinase):     $\text{Fatty Acid} + \text{CoA-SH} + \text{ATP} \xrightarrow{\text{Mg}^{2+}} \text{Fatty Acyl-CoA} + \text{AMP} + \text{PP}_i$
  • Rapid pyrophosphatase cleavage of inorganic pyrophosphate ($\text{PP}_i \rightarrow 2\text{ P}_i$) drives the reaction forward.
  • Step 1 — Transesterification by CPT-I: Carnitine palmitoyltransferase I ($\text{CPT-I}$), situated on the outer mitochondrial membrane, replaces the coenzyme A moiety with carnitine, forming fatty acyl-carnitine and releasing free cytosolic $\text{CoA-SH}$.
  • Step 2 — Translocation by CACT: Carnitine-acylcarnitine translocase ($\text{CACT}$), an inner mitochondrial membrane antiporter, imports fatty acyl-carnitine into the mitochondrial matrix while exporting free carnitine into the intermembrane space.
  • Step 3 — Re-esterification by CPT-II: Carnitine palmitoyltransferase II ($\text{CPT-II}$), on the matrix side of the inner membrane, transfers the fatty acyl chain back to mitochondrial $\text{CoA-SH}$, regenerating matrix fatty acyl-CoA and releasing carnitine.

The $\beta$-Oxidation Pathway and Energy Yield

• Reaction Sequence in the Mitochondrial Matrix:
  • $\beta$-oxidation is a cyclic pathway that oxidizes fatty acyl-CoA molecules at the $\beta$-carbon position, cleaving two-carbon acetyl-CoA units per cycle.

• Step 1 — First Oxidation (Dehydrogenation):

  • Catalyzed by Acyl-CoA Dehydrogenase.
  • Introduces a trans double bond between the $\alpha$ ($\text{C}_2$) and $\beta$ ($\text{C}_3$) carbons of fatty acyl-CoA, producing $trans\text{-}\Delta^2\text{-Enoyl-CoA}$.
  • Simultaneously reduces flavin adenine dinucleotide ($\text{FAD}$) to $\text{FADH}_2$, which shuttles electrons directly to the electron transport chain ($\text{ETC}$).

• Step 2 — Hydration:

  • Catalyzed by Enoyl-CoA Hydratase.
  • Adds a molecule of water across the $\text{C}_2\text{=C}_3$ double bond in a stereospecific manner, yielding $\text{L-}\beta\text{-Hydroxyacyl-CoA}$.

• Step 3 — Second Oxidation (Dehydrogenation):

  • Catalyzed by $\beta\text{-Hydroxyacyl-CoA Dehydrogenase}$.
  • Oxidizes the secondary hydroxyl group at the $\beta$-carbon into a keto group, forming $\beta\text{-Ketoacyl-CoA}$.
  • Reduces $\text{NAD}^+$ to $\text{NADH} + \text{H}^+$, generating reducing equivalents for Complex I of the respiratory chain.

• Step 4 — Thiolysis (Cleavage):

  • Catalyzed by $\beta\text{-Ketoacyl-CoA Thiolase}$ (Acyl-CoA acetyltransferase).

  • The bond between the $\alpha$ and $\beta$ carbons is cleaved by a molecule of coenzyme A ($\text{CoA-SH}$).

  • Releases one two-carbon molecule of acetyl-CoA and a shortened fatty acyl-CoA chain (shortened by two carbons), which re-enters the cycle.

  • Stoichiometry and ATP Yield from Palmitic Acid ($C16:0$):

• Complete breakdown of palmitate ($16\text{ carbons}$) requires $7$ successive cycles of $\beta$-oxidation.

• Gross Metabolic Products:

  • $8\text{ Acetyl-CoA}$
  • $7\text{ NADH}$
  • $7\text{ FADH}_2$

• Theoretical ATP Calculation:

  • From $7\text{ NADH}$ ($7 \times 2.5\text{ ATP}$) = $17.5\text{ ATP}$
  • From $7\text{ FADH}_2$ ($7 \times 1.5\text{ ATP}$) = $10.5\text{ ATP}$
  • From $8\text{ Acetyl-CoA}$ entering the Citric Acid Cycle ($8 \times 10\text{ ATP}$) = $80.0\text{ ATP}$
  • Gross Total Generated = $108.0\text{ ATP}$

• Energy Investment and Net Yield:

  • Activation of free palmitate to palmitoyl-CoA consumes two high-energy phosphate bonds ($\text{ATP} \rightarrow \text{AMP} + \text{PP}_i$).

  • Net ATP Yield = $108 - 2 = 106\text{ ATP}$.

  • Catabolism of Odd-Chain Fatty Acids:

• Odd-chain fatty acids undergo regular cycles of $\beta$-oxidation until the final thiolytic cleavage yields one molecule of acetyl-CoA ($2C$) and one molecule of propionyl-CoA ($3C$).

• Propionyl-CoA Conversion Pathway:

  • Carboxylation: Propionyl-CoA is carboxylated to $\text{D-methylmalonyl-CoA}$ by propionyl-CoA carboxylase, an ATP- and biotin-dependent enzyme.
  • Epimerization: Methylmalonyl-CoA epimerase converts $\text{D-methylmalonyl-CoA}$ to $\text{L-methylmalonyl-CoA}$.
  • Isomerization: Methylmalonyl-CoA mutase, requiring coenzyme $\text{B}_{12}$ (adenosylcobalamin), catalyzes an intramolecular rearrangement of $\text{L-methylmalonyl-CoA}$ to succinyl-CoA.
  • The resulting succinyl-CoA enters the Citric Acid Cycle directly, providing a glucogenic substrate from odd-chain fats.

• Regulatory Control of $\beta$-Oxidation:
  • Allosteric Inhibition via Malonyl-CoA: Malonyl-CoA, synthesized during the first step of de novo fatty acid synthesis, allosterically inhibits carnitine palmitoyltransferase I ($\text{CPT-I}$), preventing newly made fatty acids from immediately re-entering the mitochondria for oxidation.
  • Hormonal Regulation: Glucagon and adrenaline activate adipose lipolysis and promote fatty acid oxidation during fasting. Insulin promotes the dephosphorylation and inactivation of $\text{HSL}$, suppressing lipolysis.
  • Energy Charge and Redox Status: High cellular $\text{ATP}/\text{ADP}$ ratios inhibit respiratory chain turnover, leading to the accumulation of $\text{NADH}$ and $\text{FADH}_2$. Elevated $\text{NADH}/\text{NAD}^+$ and $\text{FADH}_2$ ratios feedback-inhibit $\beta\text{-hydroxyacyl-CoA dehydrogenase}$ and acyl-CoA dehydrogenase.

Biosynthesis of Triacylglycerols and De Novo Fatty Acid Synthesis

• Biosynthesis of Triacylglycerols (TAGs):
  • Anabolic process occurring primarily in the liver and adipose tissue to store surplus metabolic energy.
  • Precursors: Glycerol-3-phosphate (derived from dihydroxyacetone phosphate via $\text{GPDH}$ or direct glycerol phosphorylation by glycerol kinase in the liver) and activated fatty acyl-CoAs.

• Enzymatic Acylation Steps:

  • Acylation 1: Glycerol-3-phosphate acyltransferase ($\text{GPAT}$) transfers a fatty acyl chain to the $sn\text{-}1$ position of glycerol-3-phosphate, forming lysophosphatidic acid.

  • Acylation 2: 1-Acylglycerol-3-phosphate acyltransferase ($\text{AGPAT}$, or lysophosphatidic acid acyltransferase) esterifies a second fatty acyl-CoA to the $sn\text{-}2$ position, producing phosphatidic acid.

  • Dephosphorylation: Phosphatidic acid phosphatase ($\text{PAP}$, also known as lipin) removes the phosphate group from phosphatidic acid to yield $1,2\text{-diacylglycerol}$ ($\text{DAG}$).

  • Acylation 3: Diacylglycerol acyltransferase ($\text{DGAT}$) attaches a third fatty acyl chain to the $sn\text{-}3$ position of $\text{DAG}$, generating a triacylglycerol ($\text{TAG}$).

  • De Novo Biosynthesis of Fatty Acids (Lynen's Spiral):

• Discovered by Nobel laureate Feodor Lynen (awarded in $1964$), this extramitochondrial pathway synthesizes fatty acids from acetyl-CoA in the cytoplasm.

• Highly active in the liver, adipose tissue, lactating mammary glands, brain, and kidneys.

• The principal product of this pathway is palmitic acid ($C16:0$).

  • Citrate-Malate Shuttle (Mitochondrial Export of Acetyl-CoA):

• Acetyl-CoA is generated in the mitochondrial matrix by pyruvate dehydrogenase, but cannot directly cross the inner mitochondrial membrane.

• Intra-mitochondrial acetyl-CoA condenses with oxaloacetate via citrate synthase to produce citrate.

• Citrate is exported across the inner membrane by the tricarboxylic acid transporter.

• In the cytosol, ATP-citrate lyase cleaves citrate back into acetyl-CoA and oxaloacetate, consuming $1\text{ ATP}$.

• Cytosolic oxaloacetate is reduced to malate by cytosolic malate dehydrogenase, and malic enzyme oxidatively decarboxylates malate to pyruvate, generating cytosolic $\text{NADPH}$ required for lipogenesis.

• The Fatty Acid Synthase (FAS) Multienzyme Complex:
  • A multifunctional, homodimeric protein complex. In mammals, a single polypeptide chain contains seven distinct catalytic domains and an Acyl Carrier Protein ($\text{ACP}$) domain featuring a $4'\text{-phosphopantetheine}$ prosthetic arm.

• Step 1 — Carboxylation of Acetyl-CoA (Rate-Limiting Step):

  • Acetyl-CoA is carboxylated to form malonyl-CoA ($3C$) by acetyl-CoA carboxylase ($\text{ACC}$):       $\text{CH}_3\text{-CO-SCoA} + \text{CO}_2 + \text{ATP} \xrightarrow{\text{Biotin}} \text{COOH-CH}_2\text{-CO-SCoA} + \text{ADP} + \text{P}_i$
  • This committed reaction requires biotin and ATP.

• Step 2 — Priming and Loading:

  • Step 2A: Acetyl transacylase ($\text{AT}$) transfers the two-carbon acetyl group of acetyl-CoA onto a cysteine sulfhydryl group ($-\text{SH}$) of the condensing enzyme domain (ketoacyl synthase, $\text{KS}$).
  • Step 2B: Malonyl transacylase ($\text{MT}$) transfers the malonyl group from malonyl-CoA onto the $\text{-SH}$ group of the $\text{ACP}$ domain, forming malonyl-ACP.

• Step 3 — Condensation:

  • The condensing enzyme (3-ketoacyl synthase) catalyzes the condensation of the acetyl group ($2C$) and malonyl group ($3C$), releasing $\text{CO}_2$.
  • Produces acetoacetyl-ACP ($\beta\text{-ketoacyl-ACP}$, a four-carbon intermediate).

• Step 4 — First Reduction:

  • $\beta\text{-Ketoacyl reductase}$ ($\text{KR}$) reduces the acetoacetyl-ACP keto group to a hydroxyl group, consuming $\text{NADPH} + \text{H}^+$ to form $\beta\text{-hydroxybutyryl-ACP}$.

• Step 5 — Dehydration:

  • $\beta\text{-Hydroxyacyl-ACP dehydratase}$ ($\text{DH}$) removes a molecule of water ($\text{H}_2\text{O}$), forming a trans double bond and producing enoyl-ACP ($trans\text{-}\Delta^2\text{-enoyl-ACP}$, or crotonyl-ACP).

• Step 6 — Second Reduction:

  • Enoyl reductase ($\text{ER}$) reduces the carbon-carbon double bond using a second molecule of $\text{NADPH} + \text{H}^+$ to generate butyryl-ACP ($4\text{ carbons}$).

• Repetition of Cycles and Product Release:

  • The saturated butyryl group is transferred from $\text{ACP}$ to the condensing enzyme $\text{-SH}$ group.

  • Steps $3$ through $6$ are repeated across a total of seven cycles, adding two carbons from an incoming malonyl-CoA during each turn.

  • Upon reaching sixteen carbons (palmitoyl-ACP), thioesterase ($\text{TE}$, Step 7) hydrolyzes the thioester bond, releasing free palmitic acid ($C16:0$).

  • Regulation of De Novo Lipogenesis:

• Allosteric Regulation: High levels of cytosolic citrate allosterically activate acetyl-CoA carboxylase ($\text{ACC}$) by promoting polymer assembly. Palmitoyl-CoA, the end product of the pathway, exerts feedback inhibition on $\text{ACC}$.

• Covalent Phosphorylation: $\text{ACC}$ is inactivated through phosphorylation catalyzed by AMP-activated protein kinase ($\text{AMPK}$) when cellular energy levels are low (high AMP). High ATP levels inhibit $\text{AMPK}$, preserving $\text{ACC}$ in an active, dephosphorylated state.

• Hormonal Regulation:

  • Insulin: Stimulates lipogenesis by activating protein phosphatase 1 to dephosphorylate and activate $\text{ACC}$. Insulin also upregulates glucose uptake in adipocytes and induces pyruvate dehydrogenase and glycerol phosphate acyltransferase activity.
  • Glucagon and Epinephrine: Inhibit lipogenesis by activating cyclic AMP-dependent protein kinase A ($\text{PKA}$), which phosphorylates and inactivates $\text{ACC}$, shunting acetyl-CoA toward oxidation rather than storage.